Evidence map›Paper›PMID 33164163›Full record

ArticleDrug delivery and translational research2021

Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.

Abhijit A Date, Max Kates, Takahiro Yoshida, Taarika Babu, Umara Afzal, Pranjali Kanvinde, Alexander Baras, Nicole Anders, Ping He, Michelle Rudek and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abhijit A DateThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, USA.
Max KatesBrady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, USA.
Takahiro YoshidaBrady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, USA.
Taarika BabuDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, USA.
Umara AfzalThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, USA.
Pranjali KanvindeThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, USA.
Alexander BarasBrady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, USA.
Nicole AndersThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA.
Ping HeThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA.
Michelle RudekThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA.
Justin HanesThe Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, USA.
Trinity J Bivalacqua *Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, USA. tbivala1@jhmi.edu.
Laura M Ensign *The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, USA. lensign@jhmi.edu.ORCID 0000-0002-6949-7911

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCRR NIH HHS S10 RR026824NEI NIH HHS P30 EY001765
6 · The paper itself

Abstract

Intravesical chemotherapy is a key approach for treating refractory non-muscle-invasive bladder cancer (NMIBC). However, the effectiveness of intravesical chemotherapy is limited by bladder tissue penetration and retention. Here, we describe the development of a docetaxel nanosuspension that, when paired with a low osmolality (hypotonic) vehicle, demonstrates increased uptake by the bladder urothelium with minimal systemic exposure. We compare the bladder residence time and efficacy in an immune-competent rat model of NMIBC to the clinical comparator, solubilized docetaxel (generic Taxotere) diluted for intravesical administration. We found that only the intravesical docetaxel nanosuspension significantly decreased cell proliferation compared to untreated tumor tissues. The results presented here suggest that the combination of nanoparticle-based chemotherapy and a hypotonic vehicle can provide more efficacious local drug delivery to bladder tissue for improved treatment of refractory NMIBC.

Indexed as

NanoparticlesUrinary Bladder NeoplasmsAdministration, IntravesicalAnimalsDocetaxelImmunotherapyRatsDocetaxelChemotherapyNanomillingN-methyl-N-nitrosourea (MNU)PluronicTaxotereUrothelium

Identifiers

PMID33164163
PMCPMC10921980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.